Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: Phase 3 Results
Mavacamten was associated with improvements in patients with obstructive hypertrophic cardiomyopathy.
General Cardiology
Cardiometabolic Disease Risk Factors Among Drug Users
Researchers used data from the National Health and Nutrition Examination Survey 2009-2018 to assess the impact of drug and alcohol use on cardiometabolic disease risk factors.
Early Age at Menarche Tied to Worse Cardiovascular Health
Early menarche in women is associated with worse cardiovascular health.
Risk for Cardiac Events With Azithromycin, Amoxicillin Compared
The aim of the study was to use real-world data to compare the risk of cardiac events in new users of azithromycin vs amoxicillin.
Machine Learning to Detect ECG Electrode Misplacement
Machine learning may be useful for detecting inaccurate ECG lead placement.
No Causal Link Found Between Cardiometabolic Factors and MS Risk
No causal associations found between hypertension, systolic/diastolic blood pressures, high/low density lipoproteins, or type 2 diabetes on multiple sclerosis risk.
Early Therapy for Rheumatoid Arthritis May Slow Heart Disease
Disease-modifying antirheumatic drug therapy for rheumatoid arthritis treatment also cuts cardiovascular disease risk.
Leveraging Machine Learning for Gut Microbiota-Based CVD Screening
Dysbiosis of the gut microbiota was identified in individuals with cardiovascular disease and modeled using machine learning.
ESC Updates Guidelines for Adult Congenital Heart Disease
In 2020 European Society of Cardiology guidelines, updated recommendations are presented for the care of adult patients with congenital heart disease.
Study to Examine Efficacy of Canakinumab in COVID-19 With Acute Myocardial Injury
Recruitment has begun for study examining the efficacy of canakinumab for the treatment of patients with COVID-19 and acute myocardial injury.
-
Loading...
-
Loading...
Next post in General Cardiology
